Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Blonde

Endocrinology, Diabetes & Metabolism New Orleans, LA Medical Doctor

NPI 1821055237 CMS profile 728667

1514 Jefferson Hwy, New Orleans, LA 70121

Open in the dashboard

General payments

$141,712

148 records reported · program years 2019–2025

Research payments

$37,163

Paid to them · 48 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$48,219 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lawrence Blonde of New Orleans, LA is reported in the CMS Open Payments database as having received $141,712 across 148 general payments and $37,163 in research payments paid to them. Separately, studies naming them as principal investigator received $48,219 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,233 6
2024 General $1,200 1
2023 General $17,490 18
2023 Research $1,457 9
2022 General $9,178 6
2021 General $26,267 11
2021 Research $3,750 3
2020 General $18,384 12
2020 Research $7,977 11
2019 General $57,960 94
2019 Research $23,980 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Blonde
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Lawrence Blonde were reported at $11,233. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Lawrence Blonde Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $57,960 $494 $123–$2,253 $163
2020 $18,384 $335 $85–$1,841 $114
2021 $26,267 $398 $88–$1,981 $132
2022 $9,178 $364 $88–$1,568 $149
2023 $17,490 $420 $113–$1,614 $160
2024 $1,200 $440 $121–$1,646 $164
2025 $11,233 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $73,908 40 payments
  2. Sanofi-Aventis U.S. LLC $36,562 61 payments
  3. Corcept Therapeutics $11,357 16 payments
  4. Gilead Sciences, Inc. $4,134 7 payments
  5. Mannkind Corporation $4,027 5 payments
  6. Merck Sharp & Dohme Corporation $3,675 3 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,540 2 payments
  8. AstraZeneca Pharmaceuticals LP $2,000 1 payment
  9. Boehringer Ingelheim International GmbH $1,519 6 payments
  10. Eli Lilly and Company $861 5 payments
  11. Other $130 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $77,114 21 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,652 26 payments
  3. Travel and Lodging $25,874 68 payments
  4. Food and Beverage $3,207 30 payments
  5. Honoraria $800 1 payment
  6. Education $65 2 payments
Products named General payments · program years 2019–2025
  1. Victoza $30,329 14 payments
  2. Ozempic $11,574 9 payments
  3. Korlym $11,357 16 payments
  4. SOLIQUA 100/33 Diabetes $10,807 30 payments
  5. TOUJEO Diabetes $6,673 20 payments
  6. NO PRODUCT DISCUSSED $4,965 10 payments
  7. SOLIQUA 100/33 Endocrinology $4,698 5 payments
  8. TOUJEO Endocrine & Metabolic Diseases $4,250 1 payment
  9. SOLIQUA 100/33 Endocrine & Metabolic Diseases $4,250 1 payment
  10. AFREZZA $4,027 5 payments
  11. Other $7,865 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $32,902 38 payments
  2. Eli Lilly and Company $2,805 1 payment
  3. Corcept Therapeutics $1,457 9 payments

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record